Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity

IMPORTANCE: Although neoadjuvant endocrine therapy (NET) is an alternative to chemotherapy for strongly hormone receptor (HR)–positive and human epidermal growth factor receptor 2 (ERBB2)–negative breast cancer, evidence is currently lacking regarding the probable survival outcomes of NET in compari...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiaqiang, Lu, Chang-Yun, Chen, Ho-Min, Wu, Szu-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955271/
https://www.ncbi.nlm.nih.gov/pubmed/33710293
http://dx.doi.org/10.1001/jamanetworkopen.2021.1785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955271/
https://www.ncbi.nlm.nih.gov/pubmed/33710293
http://dx.doi.org/10.1001/jamanetworkopen.2021.1785

Ejemplares similares